Nardosinone

Research use only, not for human use.

Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways.

Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways. Nardosinone could protect against the neuronal injury exposed to OGD, which may be relevant to the promotion of PKA and ERK signaling pathway. Nardosinone enhances staurosporine- or dbcAMP-induced neurite outgrowth from PC12D cells, probably by amplifying both the MAP kinase-dependent and -independent signaling pathways of dbcAMP and staurosporine. The enhancement of NGF-induced neurite outgrowth from PC12D cells by Nardosinone involves activation of a down-stream step of the MAP kinase-dependent cascade of NGF coupled with PKC.

Nardosinone (0.1-100 microM) enhanced dibutyryl cyclic AMP (dbcAMP, 0.3 mM)- and staurosporine (10 nM)-induced neurite outgrowth from PC12D cells in a concentration-dependent manner. Nardosinone enhances a downstream step of MAP kinase in the MAP kinase-dependent signaling pathway.

——

——

Others

Other Targets

Others

Others-Field

——

23720-80-1

250.33

C15H22O3

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (998.68 mM)

CC1CCC=C2C1(C3C(CC2=O)OOC3(C)C)C

——

(-20℃)

With Ice Pack

≥ 2 years